Falco Holdings
Basic Information
- Stock Code
- 4671
- Industry
- Services
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Kyoto Prefecture
- Establishment Year
- August 1982
- Listing Year
- April 1997
- Official Website
- http://www.falco-hd.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kojin Bio, Linical, Transgenic Group, Shin Nihon Kagaku, DNA Chip Research, DVx, Egrand, H.U. Group Holdings, BML, Clip, Human Metabolome Technologies, PhoenixBio
Overview
Falco Holdings is a major holding company in the bio and pharmaceutical industry, established in 1988 with its head office in Kyoto Prefecture, engaging in clinical testing outsourcing and medical-related services.
Current Situation
Falco Holdings recorded consolidated sales of approximately ¥46 billion and operating profit of approximately ¥2.15 billion in the fiscal year ending March 2017, achieving stable growth. Its core clinical testing outsourcing business provides high-quality services to medical institutions and maintains a solid position in the industry. Through collaboration among group companies, it has developed advanced testing technologies and established a rapid testing system. In recent years, it has focused on research and development and bio-related fields by selling off its drugstore business. In terms of sustainability, it emphasizes medical safety and personal information protection, strengthening contributions to regional healthcare. In the future, it plans to introduce new technologies and expand services to adapt to changes in the medical environment with a growth strategy. Additionally, diversification of related companies has realized business risk dispersion, contributing to performance stability.
Trivia
Interesting Facts
- Group companies hold multiple patents for medical testing technologies
- Listed on the First Section of Tokyo and Osaka Stock Exchanges in 2005
- Fully withdrew from drugstore business in 2014 to specialize
- Roots trace back to Kansai Medical Testing Center founded in 1962
- Head office in Sakyo-ku, Kyoto City, located in a medical-related company cluster
- Deploys comprehensive medical services in close collaboration with regional healthcare
- Related company Falco Bio handles bio research and development
- Top-class market share in Japan's clinical testing outsourcing market
- Industry-leading early introduction of online health consultations
- Forms a large organization with over 1,400 medical professionals
Hidden Connections
- Transferred all shares of Shino Pharmacy to Matsumoto Kiyoshi in 2013, contributing to industry reorganization
- Absorbed and merged Cosmic Co., Ltd. and Falco Communications to strengthen business integration
- Collaborates with many pharmaceutical companies on clinical trials, contributing to new drug development
- Adapted to market changes through listing transition from Tokyo Stock Exchange to Osaka Stock Exchange
- Genome Business Division Head appointed as Vice President and Senior Executive Officer to advance technological strengthening
- Maintains deep partnerships with regional medical institutions, contributing to regional health maintenance
- Contributes to regional industrial development as a bio holding company headquartered in Kyoto
- Comprehensive deployment in medical and bio fields through diversified subsidiaries
Future Outlook
Growth Drivers
- Increasing demand for clinical trials domestically and internationally
- Spread of advanced medical technologies such as genome analysis
- Acceleration of medical IT and AI technology adoption
- Expansion of testing needs in aging society
- Diversification of research and development support services
- Growth in bio-pharmaceutical market
- Strengthening collaboration with regional healthcare
- Establishment of sustainable medical service provision systems
- Market expansion through global deployment
- Increased business opportunities from regulatory easing and legal amendments
- Strengthening partnerships with pharmaceutical companies
- Advanced data analysis services
Strategic Goals
- Maintain top position in clinical testing outsourcing market
- 50% improvement in operational efficiency through AI and IT utilization
- Secure domestic leadership in genome analysis field
- Build sustainable regional healthcare support model
- Achieve ¥10 billion in sales from new bio-related businesses
- Maximize group synergy for revenue expansion
- Gradual entry into overseas markets and establish business foundation
- Strengthen talent development and next-generation leader cultivation
- Obtain international certifications for medical safety and personal information protection
- Maximize quality of medical services and customer satisfaction
Business Segments
Clinical Testing Outsourcing Service
- Overview
- Provides comprehensive services from planning and operation to analysis support for clinical trials for new drug development.
- Competitiveness
- Integrated services combining clinical testing and clinical trial support
- Customers
-
- Pharmaceutical companies
- Medical institutions
- Research institutions
- Clinical trial sites
- Public research institutions
- Products
-
- Clinical trial support (CRO)
- Clinical trial outsourcing (SMO)
- Gene analysis
- Biomarker analysis
- Clinical testing
Dispensing Pharmacy Operations
- Overview
- Supports patient health management through community-based dispensing pharmacy operations.
- Competitiveness
- Dispensing network linked with medical institutions
- Customers
-
- General patients
- Medical institutions
- Nursing facilities
- Products
-
- Prescription dispensing
- OTC pharmaceutical sales
- Medication guidance service
Management Operations for Group Companies
- Overview
- Support services to promote efficiency in management operations across the group.
- Competitiveness
- One-stop support leveraging specialized knowledge
- Customers
-
- Group companies
- Internal departments
- Products
-
- Accounting & HR support
- Business efficiency services
Competitive Advantage
Strengths
- Diversified business expansion specialized in medical and bio fields
- Advanced clinical testing technology and clinical trial support expertise
- Strong collaboration with medical institution networks
- Efficient operations through group synergy
- Stable financial base and solid management structure
- Contributions to regional healthcare and reliability
- Collaborative framework with a wide range of related companies
- Long years of industry experience and track record
- High-quality research and development capabilities
- Customer satisfaction through diverse service offerings
Competitive Advantages
- Structure handling both clinical trial outsourcing (CRO) and clinical trial support (SMO)
- Rapid testing and analysis services in partnership with medical institutions
- Service expansion rooted in regional medical networks
- One-stop medical support through cooperation with related subsidiaries
- High-precision testing via introduction of latest bio technologies
- Customizable clinical trial support for pharmaceutical companies
- Long-term business investments possible due to stable financial base
- Strong systems for medical information security management
- Abundant employee experience and securing of specialized personnel
- Rapid decision-making and flexible management responses
Threats
- Business impact risks from changes in medical laws and regulations
- Competition in advanced technology development from rivals
- Trends in medical cost containment due to aging population decline
- Market fluctuations from emerging bio ventures
- Uncertainty in external environment such as infectious disease outbreaks
- Potential credit decline from information leakage risks
- Cost increases in materials and equipment due to exchange rate fluctuations
- Price pressures from intensifying competition in clinical trial market
- Decline in market competitiveness from delays in technological innovation
- Challenges in securing talent due to labor shortages
Innovations
2023: Introduction of Next-Generation Gene Analysis Technology
- Overview
- Adopted analysis equipment enabling high-precision and rapid gene testing.
- Impact
- Achieved improved testing accuracy and shortened delivery times
2022: Development of AI-Utilizing Testing Automation System
- Overview
- Introduced AI technology for image analysis and data processing into testing operations.
- Impact
- 30% improvement in operational efficiency and reduction in human errors
2021: Launch of Online Health Consultation Platform
- Overview
- Rolled out new service connecting remote patients with experts.
- Impact
- Improved customer satisfaction and increased new customer acquisition
2020: Completion of IT Security Enhancement Project
- Overview
- Introduced advanced security technologies to protect customer information.
- Impact
- Significant reduction in information leakage risks
Sustainability
- Promotion of medical waste reduction programs
- CO2 reduction through introduction of renewable energy
- Comprehensive support activities for regional healthcare
- Enhanced employee health and safety management
- Thorough personal information protection and privacy management